martes, 17 de octubre de 2023

FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-adjuvant-pembrolizumab-resectable-non-small-cell-lung-cancer

No hay comentarios:

Publicar un comentario